NTRK1 and renal cell carcinoma: Due to the poor prognosis of early-stage RCC and resistance to both radiotherapy and chemotherapy, molecular targeted drugs have become the main methods of RCC treatment, and angiogenic receptor tyrosine kinase inhibitors (TKIs) remain the first-line therapy for RCC.